Bert Verbruggen

2.1k total citations · 1 hit paper
36 papers, 1.6k citations indexed

About

Bert Verbruggen is a scholar working on Hematology, Biomedical Engineering and Genetics. According to data from OpenAlex, Bert Verbruggen has authored 36 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 9 papers in Biomedical Engineering and 6 papers in Genetics. Recurrent topics in Bert Verbruggen's work include Blood Coagulation and Thrombosis Mechanisms (16 papers), Hemophilia Treatment and Research (16 papers) and Platelet Disorders and Treatments (10 papers). Bert Verbruggen is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (16 papers), Hemophilia Treatment and Research (16 papers) and Platelet Disorders and Treatments (10 papers). Bert Verbruggen collaborates with scholars based in Netherlands, Belgium and United Kingdom. Bert Verbruggen's co-authors include I.R.O. Nováková, J.B.M. Boezeman, H. Wessels, Marijke van den Berg, Eveline P. Mauser‐Bunschoten, Jeroen Lammertyn, Piet Meijer, Waander L. van Heerde, Daan Witters and Robert Puers and has published in prestigious journals such as Blood, Langmuir and Trends in Food Science & Technology.

In The Last Decade

Bert Verbruggen

35 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability

1995 500 citations Bert Verbruggen, I.R.O. Nováková et al. Thrombosis and Haemostasis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bert Verbruggen Netherlands	21	1.0k	305	285	194	190	36	1.6k
Tohru Hayashi Japan	20	151 0.1×	103 0.3×	20 0.1×	119 0.6×	65 0.3×	66	1.1k
D.B. Rylatt Australia	18	376 0.4×	42 0.1×	84 0.3×	223 1.1×	23 0.1×	33	1.3k
Alice Ma United States	15	256 0.2×	72 0.2×	60 0.2×	137 0.7×	27 0.1×	34	681
Véronique Saada France	17	165 0.2×	112 0.4×	221 0.8×	190 1.0×	35 0.2×	53	942
Juhee Ryu South Korea	19	112 0.1×	80 0.3×	28 0.1×	225 1.2×	50 0.3×	46	1.1k
Jogin R. Wu United States	13	192 0.2×	42 0.1×	254 0.9×	106 0.5×	16 0.1×	18	612
Louis DePalma United States	15	165 0.2×	88 0.3×	43 0.2×	150 0.8×	8 0.0×	52	890
J. K. Wood United Kingdom	17	371 0.4×	263 0.9×	46 0.2×	55 0.3×	21 0.1×	48	789
B. Pötzsch Germany	15	553 0.5×	43 0.1×	44 0.2×	211 1.1×	5 0.0×	28	1.5k
Eliot C. Williams United States	15	224 0.2×	37 0.1×	38 0.1×	112 0.6×	6 0.0×	33	748

Countries citing papers authored by Bert Verbruggen

Since Specialization

Citations

This map shows the geographic impact of Bert Verbruggen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert Verbruggen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert Verbruggen more than expected).

Fields of papers citing papers by Bert Verbruggen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bert Verbruggen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert Verbruggen. The network helps show where Bert Verbruggen may publish in the future.

Co-authorship network of co-authors of Bert Verbruggen

This figure shows the co-authorship network connecting the top 25 collaborators of Bert Verbruggen. A scholar is included among the top collaborators of Bert Verbruggen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bert Verbruggen. Bert Verbruggen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verbruggen, Bert, et al.. (2024). Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL. Journal of Thrombosis and Haemostasis. 22(10). 2745–2751. 1 indexed citations

Verbruggen, Bert, Gary Moore, & Nikolaus B. Binder. (2024). Precision study of a fast and fully automated FVIII functional inhibitor test. Hämostaseologie.

Delport, Filip, Jeroen Pollet, Kris P. F. Janssen, et al.. (2012). Real-time monitoring of DNA hybridization and melting processes using a fiber optic sensor. Nanotechnology. 23(6). 65503–65503. 41 indexed citations

Meijer, Piet, et al.. (2012). Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis. Seminars in Thrombosis and Hemostasis. 38(6). 613–621. 12 indexed citations

Verbruggen, Bert, et al.. (2011). The factor VIII inhibitor assays can be standardized: results of a workshop. Journal of Thrombosis and Haemostasis. 9(10). 2003–2008. 19 indexed citations

Goodeve, Anne, et al.. (2010). Haemophilia A and von Willebrand’s disease. Haemophilia. 16(s5). 79–84. 14 indexed citations

Mast, Quirijn de, Philip G. de Groot, Waander L. van Heerde, et al.. (2010). Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. British Journal of Haematology. 151(5). 495–503. 44 indexed citations

Verbruggen, Bert, et al.. (2009). Improvements in Factor VIII Inhibitor Detection: From Bethesda to Nijmegen. Seminars in Thrombosis and Hemostasis. 35(8). 752–759. 49 indexed citations

Meijer, Piet & Bert Verbruggen. (2009). The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation. Seminars in Thrombosis and Hemostasis. 35(8). 786–793. 45 indexed citations

10.

Verbruggen, Bert. (2009). Diagnosis and quantification of factor VIII inhibitors. Haemophilia. 16(102). 20–24. 38 indexed citations

11.

Verbruggen, Bert, Piet Meijer, I.R.O. Nováková, & Waander L. van Heerde. (2008). Diagnosis of factor VIII deficiency. Haemophilia. 14(s3). 76–82. 30 indexed citations

12.

Hoogen, Martijn W.F. van den, et al.. (2008). Use of the Platelet Function Analyzer to minimize bleeding complications after renal biopsy. Thrombosis Research. 123(3). 515–522. 8 indexed citations

13.

Boekhorst, J. C. A., Bert Verbruggen, Jean‐Marc Costa, et al.. (2005). Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population. British Journal of Haematology. 131(1). 109–117. 13 indexed citations

14.

Klerk, Mariska, Petra Verhoef, Bert Verbruggen, et al.. (2002). Effect of Homocysteine Reduction by B-Vitamin Supplementation on Markers of Clotting Activation. Thrombosis and Haemostasis. 88(8). 230–235. 14 indexed citations

15.

Molen, E.F. van der, Bert Verbruggen, I.R.O. Nováková, et al.. (2000). Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. BJOG An International Journal of Obstetrics & Gynaecology. 107(6). 785–791. 76 indexed citations

16.

Kluijtmans, Leo A. J., Godfried H.J. Boers, Bert Verbruggen, et al.. (1998). Homozygous Cystathionine β-Synthase Deficiency, Combined With Factor V Leiden or Thermolabile Methylenetetrahydrofolate Reductase in the Risk of Venous Thrombosis. Blood. 91(6). 2015–2018. 43 indexed citations

17.

Verbruggen, Bert, et al.. (1998). A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada. Thrombosis and Haemostasis. 79(4). 872–875. 112 indexed citations

18.

Janssen, Mirian C. H., et al.. (1997). FACTOR VIIA DETERMINATION COMPARED TO D-DIMER IN DIAGNOSIS OF DEEP VENOUS THROMBOSIS. Thrombosis Research. 86(5). 423–426. 7 indexed citations

19.

Cornelissen, Elisabeth A. M., L.A.A. Kollée, Ronney A. De Abreu, et al.. (1992). Effects of oral and intramuscular vitamin K prophylaxis on vitamin K1, PIVKA-II, and clotting factors in breast fed infants.. Archives of Disease in Childhood. 67(10). 1250–1254. 43 indexed citations

20.

Fischer, Johan, Bert Verbruggen, H. Wessels, & C. Haanen. (1989). Interference of coumarin therapy with the "Heptest" owing to declining prothrombin concentrations.. Clinical Chemistry. 35(3). 483–486. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact